I-SPY Email List Sign-up

Thank you, your subscription is activated.

If you change your mind, you can unsubscribe at any time.

Oops! Something went wrong while submitting the form.

NEW!!! I-SPY PATIENT INFORMATION SITE. Visit: www.ispypatient.org

Featured News

Quantum Leap Healthcare Collaborative Announces Positive Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL in Neoadjuvant Breast Cancer Quantum Leap Healthcare Collaborative Announces Positive Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL in Neoadjuvant Breast Cancer

Oral Paclitaxel combination regimen has graduated from this Phase 2 trial in the triple negative breast cancer subgroup of the I-SPY2 Trial

Press Release

December 20, 2022

I-SPY updates breast cancer subtypes with response-predictive biomarkers generated across 10 therapies I-SPY updates breast cancer subtypes with response-predictive biomarkers generated across 10 therapies

I-SPY in the News

June 14, 2022

Esserman brings urgency for ‘learning healthcare’ to learn faster, better Esserman brings urgency for ‘learning healthcare’ to learn faster, better

I-SPY in the News

June 6, 2022

-- more news --

What is I-SPY?

The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster. At the heart of the I-SPY program is the ground-breaking I-SPY 2 platform trial for neoadjuvant treatment of locally advanced breast cancer.